A four-protein panel improved pancreatic cancer detection accuracy to 91.9%, outperforming the single CA19-9 protein. The panel improved early-stage (I/II) detection to 87.5% across two patient ...
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results